🔗 Visit the ClinicalTrials.gov page for NCT01548144
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion. | J Hematol Oncol | 2015 | 1.05 |
| 2 | Targeting the HGF-cMET Axis in Hepatocellular Carcinoma. | Int J Hepatol | 2013 | 0.99 |
| 3 | c-Met as a Target for Personalized Therapy. | Transl Oncogenomics | 2015 | 0.92 |
| 4 | FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer. | World J Gastroenterol | 2016 | 0.82 |
| 5 | Genetic profiles of cervical tumors by high-throughput sequencing for personalized medical care. | Cancer Med | 2015 | 0.81 |
| 6 | Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion. | Oncology | 2016 | 0.80 |
| 7 | MET inhibitors in combination with other therapies in non-small cell lung cancer. | Transl Lung Cancer Res | 2012 | 0.78 |